The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy (LRT) with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma (HCC) with beyond up-to-7 criteria.
 
Peter Robert Galle
Honoraria - Adaptimmune; AstraZeneca/MedImmune; Bayer Schering Pharma; Bristol-Myers Squibb; Ipsen; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Ipsen; Lilly; Roche
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Bayer Schering Pharma; Lilly; Sirtex Medical
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai; Roche
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); Eisai (Inst); GE Healthcare (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Josep M Llovet
Consulting or Advisory Role - Astrazeneca; Bayer; Bluejay; Boston Scientific; Bristol Myers Squibb; Captor Therapeutics Inc; Eisai; Exelixis; Genentech; Glycotest; Ipsen; Iylon; Lilly; Merck; Mina Alpha Ltd; Nucleix; Omega Therapeutics; Roche
Research Funding - Bayer (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Bayer
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Omega Therapeutics, Inc.; Ono Pharmaceutical; Roche
 
Riccardo Lencioni
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
 
Yanina Oviedo
Travel, Accommodations, Expenses - Adium Pharma; MSD
 
Kalpna Desai
Employment - Accord Healthcare
Leadership - Accord Healthcare
 
Amandine Monier
No Relationships to Disclose
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Medivir; Medivir; Merck; Pfizer
Speakers' Bureau - Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)